Delphine Kemlin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Delphine Kemlin has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Arnaud Marchant
European Plotkin Institute for Vaccinology, Université Libre de Bruxelles, 900 Route de Lennik, 170 Anderlecht, Belgium; ULB Centre for Research in Immunology (U-CRI), Université Libre de Bruxelles, 8 Rue Adrienne Bolland, 6041 Gosselies, Belgium
4 shared publications Isabelle Desombere
Laboratory of Immune Response, Scientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium
3 shared publicationsLeo Heyndrickx
Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
3 shared publications- Nicolas Gemander
European Plotkin Institute for Vaccinology, Université libre de Bruxelles (ULB), Brussels and ULB Centre for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Gosselies, Belgium; Department of Nephrology, Dialysis and Transplantation, Erasme Hospital, Université libre de Bruxelles (ULB), Brussels, Belgium
3 shared publications - Pieter Pannus
Scientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium
3 shared publications - Alain Le Moine
Department of Nephrology, Dialysis and Renal Transplantation, Hôpital Erasme, Université libre de Bruxelles Bruxelles Belgium
2 shared publications
Latest Publications
- Open Access
- 10 August 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (11) , 1857-1860
Persistent defect in SARS-CoV-2 humoral and cellular immunity in lung transplant recipients
- 10 August 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (11) , 1857-1860
Open AccessPersistent defect in SARS-CoV-2 humoral and cellular immunity in lung transplant recipients
- Open Access
- 10 February 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (5) , 649-658
Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients
- 10 February 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (5) , 649-658
Open AccessHumoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients
- Open Access
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (3) , 994-995
Hybrid immunity to SARS-CoV-2 in kidney transplant recipients and hemodialysis patients
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (3) , 994-995
Open AccessHybrid immunity to SARS-CoV-2 in kidney transplant recipients and hemodialysis patients
- Open Access
- 20 December 2022
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (12) , e0001308
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
Fractional dosing of COVID-19 vaccines could accelerate vaccination rates in low-income countries. Dose-finding studies of the mRNA vaccine BNT162b2 (Pfizer-BioNTech) suggest that a fractional dose induces comparable antibody responses to the full dose in people 0.67. Primary analysis was done on the per-protocol population, including infection naïve participants only. 145 participants were enrolled and randomized, were mostly female (69.5%), of European origin (95%), with a mean age of 40.4 years (SD 7.9). At 28 days post second dose, the geometric mean titre (GMT) of anti-RBD IgG of the reduced dose regimen (1,705 BAU/mL) was not non-inferior to the full dose regimen (2,387 BAU/mL), with a GMR of 0.714 (two-sided 95% CI 0.540–0.944). No serious adverse events occurred. While non-inferiority of the reduced dose regimen was not demonstrated, the anti-RBD IgG titre was only moderately lower than that of the full dose regimen and, importantly, still markedly higher than the reported antibody response to the licensed adenoviral vector vaccines. These data suggest that reduced doses of the BNT162b2 mRNA vaccine may offer additional benefit as compared to the vaccines currently in use in most low and middle-income countries, warranting larger immunogenicity and effectiveness trials. Trial Registration: The trial is registered at ClinicalTrials.gov (NCT04852861).
- 20 December 2022
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (12) , e0001308
Open AccessSafety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial
Fractional dosing of COVID-19 vaccines could accelerate vaccination rates in low-income countries. Dose-finding studies of the mRNA vaccine BNT162b2 (Pfizer-BioNTech) suggest that a fractional dose induces comparable antibody responses to the full dose in people 0.67. Primary analysis was done on the per-protocol population, including infection naïve participants only. 145 participants were enrolled and randomized, were mostly female (69.5%), of European origin (95%), with a mean age of 40.4 years (SD 7.9). At 28 days post second dose, the geometric mean titre (GMT) of anti-RBD IgG of the reduced dose regimen (1,705 BAU/mL) was not non-inferior to the full dose regimen (2,387 BAU/mL), with a GMR of 0.714 (two-sided 95% CI 0.540–0.944). No serious adverse events occurred. While non-inferiority of the reduced dose regimen was not demonstrated, the anti-RBD IgG titre was only moderately lower than that of the full dose regimen and, importantly, still markedly higher than the reported antibody response to the licensed adenoviral vector vaccines. These data suggest that reduced doses of the BNT162b2 mRNA vaccine may offer additional benefit as compared to the vaccines currently in use in most low and middle-income countries, warranting larger immunogenicity and effectiveness trials. Trial Registration: The trial is registered at ClinicalTrials.gov (NCT04852861).
- Open Access
Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients
As solid organ recipients are at high risk of severe COVID-19 and respond poorly to primary SARS-CoV-2 mRNA vaccination, they have been prioritized for booster vaccination. However, an immunological correlate of protection has not been identified in this vulnerable population. We conducted a prospective monocentric cohort study of 65 kidney transplant recipients who received three doses of SARS-CoV-2 BNT162b2 mRNA vaccination. Associations between symptomatic breakthrough infection (BTI) and vaccine responses, patient demographic and clinical characteristics were explored. Symptomatic COVID-19 was diagnosed in 32% of kidney transplant recipients during a period of six months after the administration of the third vaccine dose. During this period, SARS-CoV-2 delta and omicron were the dominant variants in the general population. Univariate analyzes identified avidity of SARS-CoV-2 receptor binding domain (RBD) binding IgG, neutralizing antibodies and SARS-CoV-2 S2 domain-specific IFN-γ responses as correlates of protection against BTI. Some demographic and clinical parameters correlated with vaccine responses, but none correlated with the risk of BTI. In multivariate analysis, the risk of BTI was best predicted by neutralizing antibody and S2-specific IFN-γ responses, adjusting for age, graft function and mycophenolate mofetil use. In conclusion, both antibody and T cell responses predict the risk of BTI in kidney transplant recipients who received three doses of SARS-CoV-2 mRNA vaccine. T cell responses may help compensate for the suboptimal antibody response to vaccination in this vulnerable population. One Sentence Summary: Antibody and T cell responses to booster SARS-CoV-2 vaccination predict the risk of symptomatic breakthrough infection in kidney transplant recipients
Open AccessHumoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients
As solid organ recipients are at high risk of severe COVID-19 and respond poorly to primary SARS-CoV-2 mRNA vaccination, they have been prioritized for booster vaccination. However, an immunological correlate of protection has not been identified in this vulnerable population. We conducted a prospective monocentric cohort study of 65 kidney transplant recipients who received three doses of SARS-CoV-2 BNT162b2 mRNA vaccination. Associations between symptomatic breakthrough infection (BTI) and vaccine responses, patient demographic and clinical characteristics were explored. Symptomatic COVID-19 was diagnosed in 32% of kidney transplant recipients during a period of six months after the administration of the third vaccine dose. During this period, SARS-CoV-2 delta and omicron were the dominant variants in the general population. Univariate analyzes identified avidity of SARS-CoV-2 receptor binding domain (RBD) binding IgG, neutralizing antibodies and SARS-CoV-2 S2 domain-specific IFN-γ responses as correlates of protection against BTI. Some demographic and clinical parameters correlated with vaccine responses, but none correlated with the risk of BTI. In multivariate analysis, the risk of BTI was best predicted by neutralizing antibody and S2-specific IFN-γ responses, adjusting for age, graft function and mycophenolate mofetil use. In conclusion, both antibody and T cell responses predict the risk of BTI in kidney transplant recipients who received three doses of SARS-CoV-2 mRNA vaccine. T cell responses may help compensate for the suboptimal antibody response to vaccination in this vulnerable population. One Sentence Summary: Antibody and T cell responses to booster SARS-CoV-2 vaccination predict the risk of symptomatic breakthrough infection in kidney transplant recipients